Skip to main content
OpenTrials

Clinical trial condition

Multiple Endocrine Neoplasia Type 2a

Explore clinical trials studying Multiple Endocrine Neoplasia Type 2a. Study availability and eligibility vary by location and protocol.

13 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Multiple Endocrine Neoplasia Type 2a trial results

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +19 more
Locations
  • University of Kentucky Chandler Medical Center Lexington, Kentucky, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Ohio State University Columbus, Ohio, United States
View all 45 locations
View Trial Details
Recruiting

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

NCT06523582

Conditions
Abnormalities, Multiple, Adenocarcinoma, Adenoma, +103 more
Locations
  • Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social Mexico City, Mexico
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City, Mexico
  • Red de Apoyo a la Investigación, Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México Mexico City, Mexico
View Trial Details
Completed

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

NCT03194893

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +15 more
Locations
  • Chao Family Comprehensive Cancer Center Orange, California, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Centre Francois Baclesse Caen, France
  • Centre Georges François Leclerc Dijon, France
View all 29 locations
View Trial Details
Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details
Completed

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT03780517

Conditions
Adenocarcinoma, Advanced Nonhaematologic Malignancies, Bronchial Neoplasms, +27 more
Locations
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • Institut Jules Bordet Brussels, Belgium
  • UZ Leuven Leuven, Belgium
View all 21 locations
View Trial Details

Related conditions